Skip to main content
SpringerLink
Log in

Insulin Glulisine

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

▴ Insulin glulisine is a rapid-acting human insulin analogue that has a faster onset of action and shorter duration of action than regular human insulin (RHI) in patients with type 1 or 2 diabetes mellitus and is efficacious in controlling prandial blood glucose levels in these patients.

▴ In large, well designed trials in patients with type 1 diabetes, insulin glulisine demonstrated a similar degree of glycaemic control, as measured by glycosylated haemoglobin (HbA1c) levels, to RHI after 12 weeks and insulin lispro after 26 weeks.

▴ Pre-meal insulin glulisine was also more effective than RHI at controlling 2-hour post-prandial glucose excursions in patients with type 1 or 2 diabetes over a period of 12 weeks.

▴ In patients with type 2 diabetes, insulin glulisine induced significantly greater reductions in HbAic levels and 2-hour post-breakfast and post-dinner blood glucose levels than RHI over a period of 26 weeks.

▴ Insulin glulisine was generally well tolerated by patients with type 1 or 2 diabetes and had a similar safety profile to insulin lispro or RHI. Severe hypoglycaemia was experienced by similar proportions of insulin glulisine or comparator insulin (insulin lispro or RHI) recipients with type 1 or type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. World Health Organisation. Diabetes action now [online]. Available from URL: http://www.who.int/diabetes/actionnow/en/DANbooklet.pdf [Accessed 2004 Oct 13]

  2. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321(7258): 405–12

    Article  PubMed  CAS  Google Scholar 

  3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999 Aug 14; 354 (9178): 602]. Lancet 1998 Sep 12; 352 (9131); 837–53

  4. American Diabetes Association. Insulin administration. Diabetes Care 2004 Jan; 27 Suppl. 1: S106–9

    Article  Google Scholar 

  5. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001 Oct; 22(5): 706–17

    Article  PubMed  CAS  Google Scholar 

  6. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63(16): 1743–78

    Article  PubMed  CAS  Google Scholar 

  7. Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004; 64(17): 1957–74

    Article  PubMed  CAS  Google Scholar 

  8. Wilde MI, McTavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997 Oct; 54(4): 597–614

    Article  PubMed  CAS  Google Scholar 

  9. Aventis Pharmaceuticals Inc. Apidra™ insulin glulisine (rDNA origin) injection [online]. Available from URL: http://www.fda.gov/cder/foi/label/2004/0216291bl.pdf [Accessed 2006 Mar 20]

  10. Hennige AM, Strack V, Metzinger E, et al. Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 2005 Jul 29; 48: 1891–7

    Article  PubMed  CAS  Google Scholar 

  11. Rakatzi I, Ramrath S, Ledwig D, et al. A novel insulin analog with unique properties: Lys(B3), Glu(B29) insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 2003 Sep; 52(9): 2227–38

    Article  PubMed  CAS  Google Scholar 

  12. Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced β-cell protective action. Biochem Biophys Res Commun 2003 Oct 24; 310(3): 852–9

    Article  PubMed  CAS  Google Scholar 

  13. Hennige AM, Lehmann R, Weigert C, et al. Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes 2005 Feb; 54(2): 361–6

    Article  PubMed  CAS  Google Scholar 

  14. Becker RH, Frick AD, Burger F, et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005 May; 113(5): 292–7

    Article  PubMed  CAS  Google Scholar 

  15. Becker RHA, Frick A, Wessels D. Pharmacodynamics and pharmacokinetics of a new, rapidly-acting insulin analog, insulin glulisine [abstract no. 471-P]. Diabetes 2003; 52 Suppl. 1: A110. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13–17; New Orleans (LA)

    Google Scholar 

  16. Nosek L, Becker RHA, Frick AD, et al. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin [abstract no. 588-P]. Diabetes 2004; 53 Suppl. 2: A139–140. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)

    Google Scholar 

  17. Becker RHA, Frick AD, Kapitza CK, et al. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes [abstract no. 503-P]. Diabetes 2004; 53 Suppl. 2: A119. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)

    Google Scholar 

  18. Becker RH, Frick AD, Burger F, et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005 Sep; 113(8): 435–43

    Article  PubMed  CAS  Google Scholar 

  19. Danne T, Becker RH, Heise T, et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005 Sep; 28(9): 2100–5

    Article  PubMed  CAS  Google Scholar 

  20. Frick A, Becker RHA, Wessels D, et al. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites [abstract no. 511-P]. Diabetes 2003; 52 Suppl. 1: A119. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13–17; New Orleans (LA)

    Google Scholar 

  21. Gabry KE. Application number: 21–629 (Insulin glulisine). Medical Review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/21-629_Apidra.htm [Accessed 2004 Oct 15]

  22. Frick AD, Scholtz H, Burger F, et al. Absorption of insulin glulisine when mixed with NPH insulin [abstract no. 1329-P]. Diabetes 2004; 53 Suppl. 2: A321. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)

    Article  Google Scholar 

  23. Jaros M, Martinek V, Piechatzek R, et al. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients [abstract no. 1330-P]. Diabetes 2004; 53 Suppl. 2: A321–322. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)

    Article  Google Scholar 

  24. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005 Nov; 37(11): 702–7

    Article  PubMed  CAS  Google Scholar 

  25. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine [published erratum appears in Endocr Pract 2005; 11 (2): 145]. EndocrPract 2005 Jan–Feb; 11(1): 11–7

    Google Scholar 

  26. Dailey G, Rosenstock J, Moses RWK, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004 Oct; 27(10): 2363–8

    Article  PubMed  CAS  Google Scholar 

  27. Pian LP, Sahlroot T. Application number: 21–629 (Insulin glulisine). Statistical review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/21-629_Apidra.htm [Accessed 2004 Oct 18]

  28. Hanaire-Broutin H, Schumicki DM, Hoogma RPL, et al. Safety of insulin glulisine compared with insulin aspart administered by continuous subcutaneous insulin infusion [abstract no. 826]. Diabetologia 2004; 47 Suppl. 1: A298. Plus poster presented at the 40th Annual Meeting of the European Association for the Study of Diabetes; 2004 Sep 5–9; Munich

    Google Scholar 

  29. Aventis Pharmaceuticals Inc. Aventis receives FDA approval of its rapid-acting insulin analogue Apidra® [online]. Available from URL: http://www.aventis.com [Accessed 2004 Nov 30]

  30. Aventis Pharmaceuticals Inc. Aventis announced European approval for Apidra® [online]. Available from URL: http://www.aventis.com [Accessed 2004 Dec 22]

Download references

Author information

Authors and Affiliations

  1. Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand

    Dean M. Robinson & Keri Wellington

Authors
  1. Dean M. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keri Wellington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean M. Robinson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, D.M., Wellington, K. Insulin Glulisine. Drugs 66, 861–869 (2006). https://doi.org/10.2165/00003495-200666060-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666060-00011

Keywords

Search

Navigation